The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

Published

Journal Article

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

Full Text

Duke Authors

Cited Authors

  • Ramsey, LB; Johnson, SG; Caudle, KE; Haidar, CE; Voora, D; Wilke, RA; Maxwell, WD; McLeod, HL; Krauss, RM; Roden, DM; Feng, Q; Cooper-DeHoff, RM; Gong, L; Klein, TE; Wadelius, M; Niemi, M

Published Date

  • October 2014

Published In

Volume / Issue

  • 96 / 4

Start / End Page

  • 423 - 428

PubMed ID

  • 24918167

Pubmed Central ID

  • 24918167

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

International Standard Serial Number (ISSN)

  • 0009-9236

Digital Object Identifier (DOI)

  • 10.1038/clpt.2014.125

Language

  • eng